REAL-WORLD USE OF TAFASITAMAB FOR RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA IN THE UNITED STATES BY PRIMARY REFRACTORY STATUS

Autor: Saverno, K, Savill, KMZ, Feinberg, B, Galvin, J, Pathak, P, Amoloja, T, Epperla, N, Nastoupil, LJ

Publikováno v: In Hematology, Transfusion and Cell Therapy October 2024 46 Supplement 4:S229-S229

Real-world outcomes associated with afatinib use in patients with solid tumors harboring NRG1 gene fusions.

Autor: Liu SV; Georgetown University, Washington, DC 20007, USA. Electronic address: Stephen.V.Liu@gunet.georgetown.edu., Frohn C; Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany., Minasi L; Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT 06877, USA., Fernamberg K; Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT 06877, USA., Klink AJ; Real-world Evidence and Insights, Cardinal Health Specialty Solutions, Dublin, OH, USA., Gajra A; Real-world Evidence and Insights, Cardinal Health Specialty Solutions, Dublin, OH, USA; Hematology Oncology Associates of CNY, East Syracuse, NY 13057, USA., Savill KMZ; Real-world Evidence and Insights, Cardinal Health Specialty Solutions, Dublin, OH, USA., Jonna S; Durham Veterans Affairs Hospital, Durham, NC 27705, USA.

Publikováno v: Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2024 Feb; Vol. 188, pp. 107469. Date of Electronic Publication: 2024 Jan 05.

Distinct resistance mechanisms arise to allosteric vs. ATP-competitive AKT inhibitors.

Autor: Savill KMZ; Department of Molecular Oncology, Genentech Inc., South San Francisco, CA, USA.; Cardinal Health, Dublin, OH, USA., Lee BB; Department of Molecular Oncology, Genentech Inc., South San Francisco, CA, USA., Oeh J; Department of Molecular Oncology, Genentech Inc., South San Francisco, CA, USA., Lin J; Department of Molecular Oncology, Genentech Inc., South San Francisco, CA, USA., Lin E; Department of Molecular Oncology, Genentech Inc., South San Francisco, CA, USA., Chung WJ; Department of Bioinformatics, Genentech Inc., South San Francisco, CA, USA.; Loxo Oncology at Lilly, Indianapolis, IN, USA., Young A; Department of Molecular Oncology, Genentech Inc., South San Francisco, CA, USA.; Oric Pharmaceutical, South San Francisco, CA, USA., Chen W; Department of Research Pathology, Genentech Inc., South San Francisco, CA, USA., Miś M; Department of Molecular Oncology, Genentech Inc., South San Francisco, CA, USA., Mesh K; Department of Research Pathology, Genentech Inc., South San Francisco, CA, USA., Eastham J; Department of Research Pathology, Genentech Inc., South San Francisco, CA, USA., Gnad F; Department of Bioinformatics, Genentech Inc., South San Francisco, CA, USA.; Roche Diagnostics, Basel, Switzerland., Jiang Z; Department of Bioinformatics, Genentech Inc., South San Francisco, CA, USA.; BioMap, Inc., Beijing, China., Stawiski EW; Department of Bioinformatics, Genentech Inc., South San Francisco, CA, USA.; Department of Molecular Biology, Genentech Inc., South San Francisco, CA, USA.; PACT Pharma, South San Francisco, CA, USA., Haley B; Department of Molecular Biology, Genentech Inc., South San Francisco, CA, USA., Daemen A; Department of Bioinformatics, Genentech Inc., South San Francisco, CA, USA.; Oric Pharmaceutical, South San Francisco, CA, USA., Wang X; Department of Discovery Chemistry, Genentech Inc., South San Francisco, CA, USA., Koeppen H; Department of Research Pathology, Genentech Inc., South San Francisco, CA, USA., Modrusan Z; Department of Microchemistry, Proteomics, Lipidomics and NGS, Genentech Inc., South San Francisco, CA, USA., Martin SE; Department of Molecular Oncology, Genentech Inc., South San Francisco, CA, USA., Sampath D; Department of Molecular Oncology, Genentech Inc., South San Francisco, CA, USA.; Ultragenyx Pharmaceutical, Inc., Novato, CA, USA., Lin K; Department of Molecular Oncology, Genentech Inc., South San Francisco, CA, USA. lin.kui@gene.com.

Publikováno v: Nature communications [Nat Commun] 2022 Apr 19; Vol. 13 (1), pp. 2057. Date of Electronic Publication: 2022 Apr 19.